Deals & business · first seen yesterday, updated yesterday
Envisagenics, Boehringer sign $1B deal for RNA splicing platform
A company that emerged with a new AI-powered platform nine years ago, and is focused on discovering drugs through alternative RNA splicing, has commanded a potential $1 billion or more from Boehringer Ingelheim GmbH to find precision therap…
Summary from BioWorld Articles.
Coverage 1 article · 1 outlet
-
BioWorld ArticlesEnvisagenics, Boehringer sign $1B deal for RNA splicing platform